Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of D… Read more
Bristol-Myers Squibb Company (BMY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.339x
Based on the latest financial reports, Bristol-Myers Squibb Company (BMY) has a cash flow conversion efficiency ratio of 0.339x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($6.31 Billion) by net assets ($18.60 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bristol-Myers Squibb Company - Cash Flow Conversion Efficiency Trend (1989–2024)
This chart illustrates how Bristol-Myers Squibb Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bristol-Myers Squibb Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bristol-Myers Squibb Company ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Accenture plc
NYSE:ACN
|
0.052x |
|
Danaher Corporation
NYSE:DHR
|
0.033x |
|
British American Tobacco p.l.c.
NYSE:BTI
|
0.071x |
|
S&P Global Inc
NYSE:SPGI
|
0.048x |
|
Stryker Corporation
NYSE:SYK
|
0.096x |
|
Newmont Goldcorp Corp
NYSE:NEM
|
0.069x |
|
Progressive Corp
NYSE:PGR
|
1.138x |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
0.060x |
Annual Cash Flow Conversion Efficiency for Bristol-Myers Squibb Company (1989–2024)
The table below shows the annual cash flow conversion efficiency of Bristol-Myers Squibb Company from 1989 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $16.39 Billion | $15.19 Billion | 0.927x | +97.18% |
| 2023-12-31 | $29.48 Billion | $13.86 Billion | 0.470x | +11.95% |
| 2022-12-31 | $31.12 Billion | $13.07 Billion | 0.420x | -6.72% |
| 2021-12-31 | $36.01 Billion | $16.21 Billion | 0.450x | +21.35% |
| 2020-12-31 | $37.88 Billion | $14.05 Billion | 0.371x | +137.72% |
| 2019-12-31 | $51.70 Billion | $8.07 Billion | 0.156x | -68.80% |
| 2018-12-31 | $14.13 Billion | $7.07 Billion | 0.500x | +12.33% |
| 2017-12-31 | $11.85 Billion | $5.28 Billion | 0.445x | +138.02% |
| 2016-12-31 | $16.35 Billion | $3.06 Billion | 0.187x | +28.18% |
| 2015-12-31 | $14.42 Billion | $2.10 Billion | 0.146x | -30.54% |
| 2014-12-31 | $14.98 Billion | $3.15 Billion | 0.210x | -9.70% |
| 2013-12-31 | $15.24 Billion | $3.54 Billion | 0.233x | -54.28% |
| 2012-12-31 | $13.64 Billion | $6.94 Billion | 0.509x | +66.85% |
| 2011-12-31 | $15.87 Billion | $4.84 Billion | 0.305x | +6.22% |
| 2010-12-31 | $15.64 Billion | $4.49 Billion | 0.287x | +4.45% |
| 2009-12-31 | $14.79 Billion | $4.07 Billion | 0.275x | -9.46% |
| 2008-12-31 | $12.21 Billion | $3.71 Billion | 0.304x | +1.72% |
| 2007-12-31 | $10.56 Billion | $3.15 Billion | 0.299x | +43.18% |
| 2006-12-31 | $9.99 Billion | $2.08 Billion | 0.208x | +27.27% |
| 2005-12-31 | $11.21 Billion | $1.84 Billion | 0.164x | -47.38% |
| 2004-12-31 | $10.20 Billion | $3.18 Billion | 0.311x | -13.25% |
| 2003-12-31 | $9.79 Billion | $3.51 Billion | 0.359x | +232.52% |
| 2002-12-31 | $8.76 Billion | $945.00 Million | 0.108x | -78.55% |
| 2001-12-31 | $10.74 Billion | $5.40 Billion | 0.503x | -0.71% |
| 2000-12-31 | $9.18 Billion | $4.65 Billion | 0.507x | +3.71% |
| 1999-12-31 | $8.64 Billion | $4.22 Billion | 0.489x | -2.12% |
| 1998-12-31 | $7.58 Billion | $3.78 Billion | 0.499x | +45.55% |
| 1997-12-31 | $7.22 Billion | $2.48 Billion | 0.343x | -14.68% |
| 1996-12-31 | $6.57 Billion | $2.64 Billion | 0.402x | -6.35% |
| 1995-12-31 | $5.82 Billion | $2.50 Billion | 0.429x | +6.40% |
| 1994-12-31 | $5.70 Billion | $2.30 Billion | 0.403x | -7.12% |
| 1993-12-31 | $5.94 Billion | $2.58 Billion | 0.434x | +28.93% |
| 1992-12-31 | $6.02 Billion | $2.03 Billion | 0.337x | +6.39% |
| 1991-12-31 | $5.79 Billion | $1.83 Billion | 0.317x | -2.08% |
| 1990-12-31 | $5.42 Billion | $1.75 Billion | 0.323x | +38.15% |
| 1989-12-31 | $5.08 Billion | $1.19 Billion | 0.234x | -- |